Therapeutic use of mistletoe for CD30+ cutaneous lymphoproliferative disorder/lymphomatoid papulosis [17]

Journal of the European Academy of Dermatology and Venereology

Volumn 21, Issue 4, 2007, Pages 558-560

  Seifert, Georg ^a   Tautz, C ^b   Seeger, K ^a   Henze, G ^a   Laengler, A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Gemeinschaftskrankenhaus Herdecke   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD30 ANTIGEN; STEROID; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; VISCUM FRAXINI;

AXILLARY LYMPH NODE; CASE REPORT; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LETTER; LYMPHEDEMA; LYMPHOMATOID PAPULOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RELAPSE; SCHOOL CHILD; SKIN LYMPHOMA; SKIN NODULE; SYMPTOM; T CELL LYMPHOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, SUBCUTANEOUS; LYMPHOMA, LARGE-CELL, KI-1; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMATOID PAPULOSIS; MALE; NEOPLASM RECURRENCE, LOCAL; PHYTOTHERAPY; PLANT EXTRACTS; SKIN NEOPLASMS; VISCUM;

EID: 33947408204     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01958.x     Document Type: Letter

References (10)

1. Willemze R, Meijer CJ. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 2003; 17: 1319-1332.
2. Zirbel GM, Gellis SE, Kadin ME, Esterly NB. Lymphomatoid papulosis in children. J Am Acad Dermatol 1995; 33: 741-748.
3. Wang HH, Myers T, Lach LJ, Hsieh CC, Kadin ME. Increased risk of lymphoid and nonlymphoid malignancies in patients with lymphomatoid papulosis. Cancer 1999; 86: 1240-1245.
4. Beljaards RC, Willemze R. The prognosis of patients with lymphomatoid papulosis associated with malignant lymphomas. Br J Dermatol 1992; 126: 596-602.
5. Fink-Puches R, Chott A, Ardigo M et al. The spectrum of cutaneous lymphomas in patients less than 20 years of age. Pediatr Dermatol 2004; 21: 525-533.
6. Nijsten T, Curiel-Lewandrowski C, Kadin ME. Lymphomatoid papulosis in children: A retrospective cohort study of 35 cases. Arch Dermatol 2004; 140: 306-312.
7. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 2003; 40: 244-256.
8. Reiter A, Schrappe M, Tiemann M et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: A prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899-908.
9. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H. Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 2003; 8: 109-119.
10. Augustin M, Bock PR, Hanisch J, Karasmann M, Schneider B. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 2005; 55: 38-49.